News Related to Prasinezumab

Related coverage linked through entity extraction aliases.

Prothena Reports 2025 Results as Partners Advance Phase 3 Trials in Parkinson's, ATTR-CM

Mar 22, 2026

Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.

Prothena Q4 2025 Earnings: Two Partnered Programs Enter Phase III, Cash Position Exceeds Guidance

Feb 21, 2026

Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.